Skip to main content

Poxvirus Cancer Therapy

Buy Article:

$105.00 plus tax (Refund Policy)

Despite many advances in chemotherapy and other medical techniques, patients with cancer often develop local recurrence or metastatic spread. Recent advances in molecular biology and tumor immunology have led to the design of many new anti-tumor vaccines. Such approaches are now using recombinant viruses to treat different types of cancer. From these new developments, innovative fields are emerging: vaccine virotherapy, viral immunotherapy, oncolytic virotherapy and drug virotherapy. Many viruses are currently exploited as recombinant vectors and each offers natural or synthetic characteristics that may provide unique means to treat cancer. Poxviruses are large double stranded DNA viruses that offer many advantageous characteristics as recombinant vectors. Poxvirus-based vectors offer essentially unlimited possibilities for genetic manipulation due to the large size of their DNA and high degree of safety. Vaccinia virus, the prototype virus of the Orthopoxvirus genus that was extensively used to eradicate Smallpox, and other poxviruses are now being considered and used for the treatment of cancer. This review will cover their utilization as anti-cancer therapeutics by describing recent patents (2000-2005).

No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: MVA; Poxvirus; canarypox; cancer; fowlpox; immunotherapy; oncolytic virus; vaccine; vaccinia virus; virotherapy

Document Type: Research Article

Affiliations: New Emerging Pathogens Initiative, Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL. USA 32610.

Publication date: 2006-11-01

More about this publication?
  • Recent Patents on Anti-Infective Drug Discovery publishes review articles on recent patents in the field of anti-infective drug discovery e.g. on novel bioactive compounds, analogs & targets. A selection of important and recent patents on anti-infective drug discovery is also included in the journal. The journal is essential reading for all researchers involved in anti-infective drug design and discovery.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more